Core Viewpoint - Teleflex Incorporated has successfully completed the acquisition of substantially all of the Vascular Intervention business from BIOTRONIK SE & Co. KG, enhancing its portfolio and global presence in the cath lab and peripheral intervention market [1][3][5]. Acquisition Details - The acquisition was finalized for a cash payment of €760 million, subject to certain adjustments [2]. - The Vascular Intervention business includes a comprehensive portfolio for coronary and peripheral interventions, featuring key products such as the Pantera™ Lux™ Drug-Coated Balloon Catheter and the Orsiro™ Mission Drug Eluting Stent [3][4]. Financial Outlook - The acquired products are expected to generate revenues of €177 million ($204 million) in the second half of 2025, with an anticipated €91 million ($105 million) for the fourth quarter of 2025 [5]. - From 2026 onwards, annual constant currency revenue growth of 6% or better is expected from the acquired products [5][6]. Strategic Implications - The acquisition will allow Teleflex to invest in the clinical trial program for Freesolve™, a sirolimus-eluting Resorbable Metallic Scaffold technology, with plans for a U.S. pivotal study [4]. - The integration of the Vascular Intervention business is anticipated to enhance Teleflex's innovation pipeline and position the company to leverage emerging technologies in the market [3][4].

Core Insights - Teleflex Incorporated announced findings from a multinational study demonstrating the efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters (CVCs) in reducing central line-associated bloodstream infections (CLABSIs) by 70.5% [2][3][4] Study Findings - The study involved over 6,670 patients from 12 Intensive Care Units across eight countries, including India, Malaysia, Papua New Guinea, Colombia, Egypt, and Turkey [1] - Patients using chlorhexidine-impregnated CVCs had a significantly lower incidence of infections caused by various pathogens, including gram-negative and gram-positive bacteria, as well as fungi [4][7] - The study highlighted that unprotected CVCs may pose an independent risk factor for CLABSI compared to chlorhexidine-impregnated CVCs, even with adherence to best practices [3][7] Implications for Teleflex - The results reinforce Teleflex's claims regarding the effectiveness of its Arrowg+ard Blue™ and Arrowg+ard Blue Plus™ CVCs against common CLABSI pathogens [4] - The company aims to enhance healthcare quality through innovative medical technologies, positioning itself as a trusted partner in the healthcare sector [5][6]

Core Insights - Teleflex Incorporated has launched two initiatives to raise awareness about benign prostatic hyperplasia (BPH) during Men's Health Month, focusing on quality-of-life issues and potential rectal toxicity from prostate cancer radiation treatment [3][8]. Group 1: Awareness Initiatives - The initiatives include the "Prostate Monster" ad campaign and the Prostate Education Express, a mobile training center that will tour major U.S. cities throughout 2025 [4][5]. - The Prostate Education Express aims to educate both physicians and the community about BPH and the benefits of the UroLift™ System and Barrigel™ rectal spacer [4][7]. Group 2: UroLift™ System - The UroLift™ System is a minimally invasive treatment for BPH symptoms, indicated for men aged 45 and older, and has been used to treat over 500,000 men globally [10][6]. - A clinical study showed a low retreatment rate of about 2-3% per year, indicating the durability of the UroLift™ System [10]. Group 3: Barrigel™ Rectal Spacer - Barrigel™ rectal spacer is the first hyaluronic acid rectal spacer designed to protect the rectum during radiation therapy for prostate cancer, with over 50,000 men treated [12][8]. - A clinical study found that 98.5% of men treated with Barrigel™ achieved at least a 25% reduction in radiation to the rectum, with an average reduction of 85% [8].

Core Insights - Teleflex Incorporated has published its 2024 Global Impact Report, highlighting its achievements and future goals in Corporate Social Responsibility (CSR) [1][2] - The report aligns with major sustainability frameworks including the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB), and Taskforce on Climate-Related Financial Disclosures (TCFD) [1] CSR Pillars - The 2024 Global Impact Report details accomplishments and future plans across four CSR pillars: Community & Sustainable Healthcare, Planet & Environment, People, and Ethics & Governance [2] Key Highlights - The report showcases Teleflex's ongoing commitment to CSR and the recognition it has gained among stakeholders, reflecting the pride of employees in the company's impact on the planet and society [2] - Teleflex has conducted a double materiality assessment in line with the E.U. Corporate Sustainability Reporting Directive to ensure its CSR strategy remains relevant [7] - The company has committed to the World Economic Forum Zero Health Gaps Pledge, aiming for equitable access to healthcare [7] - In 2024, Teleflex achieved ISO 14001 certification for 6 sites and plans to expand this certification in the future [7]

Core Insights - Teleflex Incorporated presented new clinical data at the 2025 American Urological Association Annual Meeting, highlighting the UroLift™ System's advantages over Rezūm and tamsulosin in terms of early patient satisfaction, rapid symptom relief, and sexual function outcomes [2][3] Group 1: UroLift™ System Findings - The UroLift™ System demonstrated significantly higher patient satisfaction at two weeks and one month post-treatment compared to Rezūm, with shorter catheterization times and improved symptom relief [5] - At three months, patients treated with the UroLift™ System showed significantly better symptom improvement and sexual function outcomes compared to those on tamsulosin, with 70% of men on medication opting to switch to UroLift™ [5] - Real-world data from the American Urological Association Quality Registry (AQUA) confirmed that BPH drugs provide limited improvement, while the UroLift™ System offers rapid symptom score improvement at three months [5] Group 2: Safety of Stabilized Hyaluronic Acid (sHA) - The study confirmed the safety of stabilized hyaluronic acid as a rectal spacer, showing a low incidence of rectal wall infiltration and no severe complications, reinforcing its use during prostate cancer treatment [4][5] - The sHA rectal spacer allows for individualized spacing and is effective in protecting patients during radiation therapy, with a focus on its reversibility as a clinical advantage [4]

Teleflex (TFX) 2025 Conference May 14, 2025 04:40 PM ET Speaker0 My name is Craig Bijou, one of the med tech analysts here at BofA. And it's a pleasure to have Teleflex here from the company, Liam Kelly, CEO and Larry Koosh, vice president investor relations and strategy development. Thank you guys for coming. Speaker1 Thanks for having us. Maybe Speaker0 just want to start with, let's start with Q1 results. You're a couple of weeks removed from that. Just talk about, I guess, some of the, I I guess, how Q1 ...

Core Insights - The Titan SGS™ Stapler is associated with significantly lower rates of postoperative gastroesophageal reflux disease (GERD) and shorter hospital stays compared to traditional multi-fire staplers in robotic-assisted laparoscopic sleeve gastrectomy (LSG) procedures [1][3][4] - A retrospective analysis of 257 patients showed that at one year post-procedure, 7.1% of patients using the Titan SGS™ Stapler reported GERD, compared to 26.4% in the multi-fire cohort [3][4] - The study highlights the importance of consistent surgical techniques in achieving better patient outcomes, particularly in reducing GERD incidence [2][3] Company Overview - Teleflex Incorporated is a leading global provider of medical technologies, focusing on improving health and quality of life through innovative solutions [5][6] - The Titan SGS™ Stapler is the first single-fire surgical stapler specifically designed for sleeve gastrectomy pouch creation, featuring a 23cm staple line for improved surgical outcomes [3][4] - The company aims to enhance the adoption of bariatric surgery by addressing common postoperative complications such as GERD [3][5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Teleflex Incorporated due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a significant drop in Teleflex's stock price, which fell by 21.6% on February 27, 2025, following the announcement of a company split and a €760 million deal with Biotronik [3]. - Shareholders who purchased Teleflex securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering hundreds of millions for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and ranking highly in the number of settlements since 2013 [4].

NEW YORK, May 1, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Teleflex Incorporated (NYSE: TFX) resulting from allegations that Teleflex may have issued materially misleading business information to the investing public.So What: If you purchased Teleflex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. Th ...

LOS ANGELES, May 1, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Teleflex Incorporated ("Teleflex" or "the Company") (NYSE: TFX) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Teleflex is the subject of an article published by Fierce Biotech on February 27 ...